A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer

PURPOSE: Despite the efficacy of abiraterone, a CYP17A1 inhibitor, in metastatic castration-resistant prostate cancer (CRPC), nearly all patients develop resistance. The purpose of this phase II study was to evaluate mechanisms of resistance to more complete androgen synthesis inhibition with abirat...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Cancer Res
Huvudupphovsmän: McKay, Rana R., Werner, Lillian, Mostaghel, Elahe A., Lis, Rosina, Voznesensky, Olga, Zhang, Zhenwei, Marck, Brett T., Matsumoto, Alvin M., Domachevsky, Liran, Zukotynski, Katherine A., Bhasin, Manoj, Bubley, Glenn J., Montgomery, Bruce, Kantoff, Philip W., Balk, Steven P., Taplin, Mary-Ellen
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2016
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5315609/
https://ncbi.nlm.nih.gov/pubmed/27683182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0987
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk